Ā | Healthy control subjects (nā=ā32) | Pregnant patients with RA (nā=ā252) | Ā | Ā | Ā | Ā | Ā | Ā |
---|---|---|---|---|---|---|---|---|
Mean age at delivery in years (SD) | 32.1 (4.4) | 32.8 (3.7) | Ā | Ā | Ā | Ā | Ā | Ā |
Median disease duration in years at first visit (range) | Ā | 4.9 (0.2-28.6) | Ā | Ā | Ā | Ā | Ā | Ā |
ACPA-positive patients, n (%) | Ā | 153/252 (61) | Ā | Ā | Ā | Ā | Ā | Ā |
RF-positive patients, n (%) | Ā | 161/239 (67) | Ā | Ā | Ā | Ā | Ā | Ā |
ACPA- and/or RF-positive patients, n (%) | Ā | 181/252 (72) | Ā | Ā | Ā | Ā | Ā | Ā |
Erosive disease, n (%) | Ā | 150/246 (61) | Ā | Ā | Ā | Ā | Ā | Ā |
Response during pregnancya, n (%) | Ā | 56/120 (47) | Ā | Ā | Ā | Ā | Ā | Ā |
Flare during post-partum period, n (%) | Ā | 69/223 (31) | Ā | Ā | Ā | Ā | Ā | Ā |
Per time point | Ā | Pre-conception | First trimester | Second trimester | Third trimester | 6 Weeks post-partum | 12 Weeks post-partum | 26 Weeks post-partum |
DAS28, mean (SD) | Ā | 3.6 (1.1) | 3.6 (1.1) | 3.6 (1.1) | 3.3 (1.1) | 3.3 (1.1) | 3.6 (1.2) | 3.4 (1.1) |
Use of prednisone, n (%) | Ā | 37/121 (31) | 79/223 (35) | 86/234 (37) | 81/239 (34) | 84/240 (35) | 87/242 (36) | 78/242 (32) |
Use of sulphasalazine, n (%) | Ā | 41/121 (34) | 62/223 (28) | 64/234 (27) | 61/239 (26) | 60/240 (25) | 72/242 (30) | 70/242 (29) |
Use of hydroxychloroquine, n (%) | Ā | 9/121 (7) | 5/223 (2) | 5/234 (2) | 4/239 (2) | 9/240 (4) | 18/242 (7) | 17/242 (7) |
Use of methotrexate, n (%) | Ā | 0/121 (0) | 0/223 (0) | 0/234 (0) | 0/239 (0) | 34/240 (14) | 59/242 (24) | 74/242 (31) |
Use of leflunomide, n (%) | Ā | 0/121 (0) | 0/223 (0) | 0/234 (0) | 0/239 (0) | 0/240 (0) | 3/242 (1) | 4/242 (2) |
Use of TNF inhibitors, n (%) | Ā | 5/121 (4) | 0/223 (0) | 0/234 (0) | 0/239 (0) | 13/240 (5) | 23/242 (10) | 29/242 (12) |